Nicotine: Clinical Trials

41 trials of Nicotine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 2 recruiting, 1 not yet recruiting, 1 unknown. 41 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 141Completed 36, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1
Phase 27Completed 7

Follow Nicotine: new trials by email Literature Review of Nicotine trials Research Report on Nicotine

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Sweeteners on the Addictive Threshold of Nicotine
Nicotine 0.05 mg/pulse and 0.1 mg/pulse, Saline Placebo (0.5mL injection), sucralose - Smoking ( Cigarette)
Phase 1Not yet recruitingYale University362026-09-012026-08-31
Comparative Evaluation of Nicotine Analogs
Biospecimen Collection, Nicotine, 6-Methyl Nicotine - Tobacco-Related Carcinoma, Addiction
Phase 1RecruitingOhio State University Comprehensive Cancer Center702026-05-292026-06-26
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
(S)-Nicotine, (R)- nicotine, Racemic nicotine - Nicotine Dependence, Nicotine Vaping
Phase 1RecruitingUniversity of California, San Francisco182024-12-062026-05-14
Effects of E-cigarette Flavors on Youth TCORS 2.0
Flavoring Agents, Nicotine - Nicotine Use Disorder
Phase 1CompletedYale University422022-11-072024-08-09
Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers
Nicotine, Cigarette - Nicotine Withdrawal, Nicotine Addiction
Phase 1CompletedJohns Hopkins University712022-07-272026-07-23
Effects of Menthol in E-cigarettes on Smoking Behaviors
Nicotine - Nicotine Dependence
Phase 1CompletedYale University142022-05-102026-06-16
Nicotine Differences in Smokers
0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine, Saline - Nicotine Dependence
Phase 1CompletedYale University112022-02-162023-12-11
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza) - Tobacco Use Disorder
Phase 1CompletedHALEON222021-09-012024-03-21
Behavioral Pharmacology of Cannabis and Nicotine
Cannabis, Nicotine - Cannabis, Nicotine
Phase 1CompletedJohns Hopkins University262020-09-152024-04-17
Effects of E-Cigarette Flavors on Adults TCORS 2.0
Nicotine, Flavor - Nicotine Use Disorder
Phase 1CompletedYale University1302019-05-142025-12-19
Effects of Commonly Used Medications on Mood and Choice
Placebo, Methylphenidate, Nicotine - Healthy
Phase 1CompletedJohns Hopkins University252018-10-022026-02-02
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine
Placebo, Nicotine, AVL-3288 - Cognitive Change
Phase 1WithdrawnUniversity of Maryland, Baltimore2018-05-012024-11-06
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2
Nicotine, Experimental Flavor, Menthol Flavor - Nicotine Dependence
Phase 1CompletedYale University562017-05-022020-05-04
Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03 mg), Behavioral Activation - Smoking
Phase 1 / Phase 2CompletedMaggie M Sweitzer, PhD352017-02-012022-06-28
Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
Habitrol, Placebo to Habitrol - Sarcoidosis
Phase 1 / Phase 2CompletedOhio State University502015-10-212025-04-24
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1
Nicotine, Low Dose Menthol, High Dose Menthol - Nicotine Dependence, Other Tobacco Product
Phase 1CompletedYale University592014-10-232020-05-04
Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine: Electronic Cigarette and Cigarette
Nicotine - Nicotine Use Disorder
Phase 1CompletedParc de Salut Mar122014-10-012015-07-30
Effects of Hallucinogens and Other Drugs on Mood and Performance
Hallucinogens and psychoactive substances - Healthy
Phase 1CompletedJohns Hopkins University202014-04-012019-05-16
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
Cocaine hydrochloride, Exercise, Nicotine - Cocaine Dependence
Phase 1CompletedYale University52013-10-012023-02-16
Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge
Nicotine (Pharmaceutical Productions Inc.) - Nicotine Pharmacokinetic Study
Phase 1CompletedPharmaceutical Productions Inc.62013-06-012016-03-30

Showing 20 of 41. Sign in to see all of them.

Conditions studied

Tobacco Use Disorder (15)  ·  Smoking (8)  ·  Smoking Cessation (5)  ·  Cigarette Smoking (3)  ·  Vaping (3)  ·  Cognitive Dysfunction (2)  ·  Substance-Related Disorders (2)  ·  Alzheimer Disease (1)  ·  Behavior, Addictive (1)  ·  Cocaine-Related Disorders (1)  ·  Cognition Disorders (1)  ·  Consciousness Disorders (1)  ·  Dementia (1)  ·  Down Syndrome (1)  ·  Marijuana Abuse (1)

Sponsors

Yale University (11)  ·  GlaxoSmithKline (5)  ·  Johns Hopkins University (4)  ·  National Institute on Drug Abuse (NIDA) (3)  ·  Contract Research Organization el AB (1)  ·  HALEON (1)  ·  Maggie M Sweitzer, PhD (1)  ·  McNeil AB (1)  ·  National Institute on Aging (NIA) (1)  ·  Neuraltus Pharmaceuticals, Inc. (1)  ·  Ohio State University (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Parc de Salut Mar (1)  ·  Pharmaceutical Productions Inc. (1)  ·  University of California, Los Angeles (1)

Countries

United States (34)  ·  Sweden (2)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Mehmet Sofuoglu, M.D., Ph.D. (2)  ·  Abrahan N Lieberman, MD (1)  ·  Alexander C Conley, PhD (1)  ·  Carol Myers, Ph.D. (1)  ·  Christopher B Harte, MA (1)  ·  Dana Cavallo, Ph.D. (1)  ·  Dana Cavallo, PhD (1)  ·  Deepak C D'Souza, M.D. (1)  ·  Dustin C Lee, Ph.D. (1)  ·  Edythe D London, Ph.D. (1)  ·  Elisabeth Kruse, PhD (1)  ·  Erik Lunell, MD, PhD (1)  ·  Frank Vocci, Ph.D (1)

Results publications

PMID 22717030, PMID 24075893, PMID 25361769, PMID 30027479, PMID 31133957, PMID 32297782, PMID 33089005, PMID 34029565, PMID 38152462, PMID 40489161, PMID 41249021

NIH funding

U54DA036151 (4), K23DA039294 (1), R01AG022462 (1), R01DA003890 (1), R01DA008075 (1), R01DA055962 (1), R01DA057282 (1), R03DA027474 (1), R21DA044377 (1), R41DA033710 (1)